Renal · Diabetic Kidney Disease
The facts most likely to be tested
The earliest clinical evidence of diabetic nephropathy is microalbuminuria, defined as a urine albumin-to-creatinine ratio (UACR) between 30 and 300 mg/g.
Kimmelstiel-Wilson nodules, which are nodular glomerulosclerosis, represent the pathognomonic histologic finding of diabetic nephropathy.
ACE inhibitors or ARBs are the first-line pharmacologic therapy for patients with diabetes, hypertension, and albuminuria to provide renoprotection.
SGLT2 inhibitors are indicated in patients with diabetic kidney disease to reduce the risk of progression to end-stage renal disease (ESRD) and cardiovascular mortality.
Hyperglycemia induces non-enzymatic glycosylation of the glomerular basement membrane (GBM), leading to hyaline arteriolosclerosis of both the afferent and efferent arterioles.
The initial physiologic change in diabetic nephropathy is glomerular hyperfiltration, which manifests as an increased glomerular filtration rate (GFR).
Annual screening for diabetic nephropathy in patients with Type 2 Diabetes should begin at the time of diagnosis using a spot urine albumin-to-creatinine ratio.
Vignette unlocked
A 58-year-old male with a 15-year history of Type 2 Diabetes Mellitus presents for a routine follow-up. His blood pressure is 142/90 mmHg, and his BMI is 31 kg/m². Laboratory studies reveal a serum creatinine of 1.1 mg/dL and a urine albumin-to-creatinine ratio of 150 mg/g. He is currently taking metformin and glipizide. His physical examination is notable for mild bilateral pedal edema.
What is the most appropriate next step in the management of this patient's renal health?
Initiate an ACE inhibitor or ARB.
The patient has evidence of microalbuminuria, and initiating an ACE inhibitor or ARB is the standard of care to provide renoprotection and slow the progression of diabetic nephropathy.
Full handout
High yield triage
Etiology / Epidemiology
Leading cause of end-stage renal disease (ESRD) in the US. Driven by hyperglycemia and hypertension.
Clinical Manifestations
Often asymptomatic until advanced. Look for Kimmelstiel-Wilson nodules and microalbuminuria.
Diagnosis
Screen with spot urine albumin-to-creatinine ratio (UACR). Threshold for microalbuminuria is 30-300 mg/g.
Treatment
First-line: ACE inhibitors or ARBs. Do not combine ACEi and ARBs.
Prognosis
Progression to ESRD requires dialysis or transplant. Monitor eGFR and UACR annually.
Full handout
Epidemiology & Etiology
Diabetic nephropathy affects approximately 30-40% of patients with Type 1 and Type 2 diabetes. Chronic hyperglycemia induces non-enzymatic glycosylation of basement membranes. Hypertension acts as a critical force multiplier for glomerular damage.
Pertinent Anatomy
The glomerulus is the primary site of injury. Damage to the podocytes and the glomerular basement membrane (GBM) leads to loss of charge selectivity and subsequent proteinuria.
Pathophysiology
Hyperglycemia triggers hyperfiltration and glomerular hypertrophy. Advanced glycation end-products cause mesangial expansion. This culminates in Kimmelstiel-Wilson nodules, which are pathognomonic for diabetic glomerulosclerosis.
Clinical Manifestations
Early stages are clinically silent. Patients may present with peripheral edema or worsening hypertension. Red flags include rapid decline in eGFR or sudden onset of nephrotic syndrome (proteinuria >3.5g/day).
Diagnosis
Annual screening is mandatory for all diabetics using the spot urine albumin-to-creatinine ratio (UACR). A value of 30-300 mg/g indicates microalbuminuria; >300 mg/g indicates macroalbuminuria. A renal biopsy is the gold standard but is rarely performed unless the diagnosis is unclear.
Treatment
Initiate ACE inhibitors or ARBs for all patients with albuminuria to provide renoprotection. Contraindicated in pregnancy due to fetal renal dysgenesis. Optimize glycemic control with SGLT2 inhibitors, which provide significant cardiorenal protection. Avoid NSAIDs to prevent acute kidney injury.
Prognosis
Progression is measured by the decline in eGFR. Patients with macroalbuminuria are at high risk for ESRD and cardiovascular mortality. Strict control of blood pressure (<130/80 mmHg) is essential to slow disease progression.
Differential Diagnosis
Hypertensive nephrosclerosis: usually associated with long-standing HTN without significant proteinuria
Glomerulonephritis: presents with active urine sediment (RBC casts, hematuria)
Renal artery stenosis: suspect if creatinine rises >30% after starting ACEi
Multiple myeloma: check for Bence-Jones proteins and lytic bone lesions
Polycystic kidney disease: look for palpable kidneys and family history